T. Rowe Price Associates
NPCE icon

T. Rowe Price Associates’s Neuropace NPCE Stock Holding History

T. Rowe Price Associates’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Buy
17,308
+2,472
+17% +$37.1K ﹤0.01% 2795
2025
Q4 		$230K Buy
14,836
+2,778
+23% +$37.1K ﹤0.01% 2762
2025
Q3 		$125K Hold
12,058
– – ﹤0.01% 2887
2025
Q2 		$135K Buy
+12,058
New +$151K ﹤0.01% 2831

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

T. Rowe Price Associates's NPCE Position: Q1 2026 in Review

T. Rowe Price Associates increased its Neuropace (NPCE) stake by 17% in Q1 2026, buying an estimated $37.1K and bringing the position to 17,308 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #2795.

T. Rowe Price Associates first reported a position in NPCE in Q2 2025 and has held it in 4 quarters since. The position peaked at $230K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • T. Rowe Price Associates held 17,308 shares of Neuropace worth $228K as of Q1 2026.
  • T. Rowe Price Associates bought 2,472 Neuropace shares in Q1 2026, an estimated $37.1K.
  • Neuropace made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2795 holding.
  • T. Rowe Price Associates first reported a position in Neuropace in Q2 2025 and has held it in 4 quarters since.
  • T. Rowe Price Associates's Neuropace position peaked at $230K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.